Deka Biosciences plans to expand its 14,000 square foot office and lab space at its Germantown facility in the United States.
To advance the development of their innovative cytokine therapeutics, the new facility will house a cutting-edge research and development, process development, and manufacturing facility.
This will be the first building in the Washington, Maryland, and Virginia region, to house a dual targeted cytokine development lab, and the only company in the United States working on a similar treatment.
At 20380 Seneca Meadows Parkway, the new headquarters will be situated.
Deka estimates that the project will be finished in the first quarter of 2023.
In collaboration with Minkoff Development, CBRE, and Facility Logix, the facility was acquired. Design and construction of the facility followed.